After having covid; Maternal exposure before pregnancy; PREVIOUSLY ADMINISTERED PRODUCT PFIZER BIONTECH 15 APRIL 2021 AND 09 MAY 2021; PREVIOUSLY ADMINISTERED PRODUCT PFIZER BIONTECH 15 APRIL 2021 AND 09 MAY 2021; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of COVID-19 (After having covid), MATERNAL EXPOSURE BEFORE PREGNANCY (Maternal exposure before pregnancy), INTERCHANGE OF VACCINE PRODUCTS (PREVIOUSLY ADMINISTERED PRODUCT PFIZER BIONTECH 15 APRIL 2021 AND 09 MAY 2021) and COVID-19 IMMUNISATION (PREVIOUSLY ADMINISTERED PRODUCT PFIZER BIONTECH 15 APRIL 2021 AND 09 MAY 2021) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Previously administered products included for COVID-19 prophylaxis: Pfizer / BioNTech (Dose Number: 1 Batch/Lot No: EW0164 Location of injection: Arm Left) on 15-Apr-2021 and Pfizer / BioNTech (Dose Number: 2 Batch/Lot No: EW0167 Location of injection: Arm Left) on 09-May-2021. Past adverse reactions to the above products included No adverse event with Pfizer / BioNTech and Pfizer / BioNTech. Concurrent medical conditions included Allergy. Concomitant products included ENOXAPARIN SODIUM, L-METHYLFOLATE, CYANOCOBALAMIN (B-12), COLECALCIFEROL (D3), DOCOSAHEXAENOIC ACID (PRENATAL DHA) and ACETYLSALICYLIC ACID (ASPIRIN LOW) for an unknown indication.    On 02-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 31-Oct-2022. On 02-Dec-2021, the patient experienced MATERNAL EXPOSURE BEFORE PREGNANCY (Maternal exposure before pregnancy), INTERCHANGE OF VACCINE PRODUCTS (PREVIOUSLY ADMINISTERED PRODUCT PFIZER BIONTECH 15 APRIL 2021 AND 09 MAY 2021) and COVID-19 IMMUNISATION (PREVIOUSLY ADMINISTERED PRODUCT PFIZER BIONTECH 15 APRIL 2021 AND 09 MAY 2021). On an unknown date, the patient experienced COVID-19 (After having covid). On 02-Dec-2021, MATERNAL EXPOSURE BEFORE PREGNANCY (Maternal exposure before pregnancy) had resolved. At the time of the report, COVID-19 (After having covid), INTERCHANGE OF VACCINE PRODUCTS (PREVIOUSLY ADMINISTERED PRODUCT PFIZER BIONTECH 15 APRIL 2021 AND 09 MAY 2021) and COVID-19 IMMUNISATION (PREVIOUSLY ADMINISTERED PRODUCT PFIZER BIONTECH 15 APRIL 2021 AND 09 MAY 2021) outcome was unknown.            Patient last menstrual period date was 17-JAN-2022.  Concomitant medications proprietary name include-Itlafarmer, MethylPro, Nature's blend(B-12), Nature's blend(D3),Garden of life, Sisu (Multi Expecting Prenatal), Bayer.  No treatment medications were reported.  Patient taking any other medications/products within 2 weeks of starting COVID-19 treatment.   Patient took non-company product on from 17 -JUN-2022 to 22-JUN-2022 for treatment of COVID-19 with batch number-GC4027.  It was reported that after patient had covid and felt better, patient became sick again with the following symptoms - Congestion from 26-Jun-2022 to present , Runny Nose  from 27-Jun-2022  to 3-Jul-2022,  tiredness from 27-Jun-2022  to present ,  low fever (99.7) from 28-Jun-022 to 29-Jun-2022 , cough from 28-Jun-2022  to present  and Headache  from 29-Jun-2022 to 1-Jul-2022.  Company Comment: This spontaneous case concerns a 34-year-old female patient, with no relevant medical history, who experienced unexpected, non-serious AESI Covid19, approximately 6 months after receiving a dose of mRNA-1273 (third dose in a Covid19 vaccination schedule).  Maternal exposure before pregnancy was also reported; she received mRNA-1273 approximately 1 and a half months prior to date of last menstrual period.  She took an unspecified drug for Covid19 treatment, after which she became sick again with symptoms of runny nose, tiredness, low fever, cough, and headache.  Additionally, she previously received 2 doses of a different Covid19 vaccine Pfizer (interchange of vaccine products/revaccination with different Covid19 vaccine).  The ongoing Covid19 pandemic could be a contributory factor.  The benefit risk relationship of mRNA-1273 is not affected by this report.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 11-Jul-2022: Follow-up was received on 11-JUL-2022 contains significant information. Medical history was updated.; Sender's Comments: This spontaneous case concerns a 34-year-old female patient, with no relevant medical history, who experienced unexpected, non-serious AESI Covid19, approximately 6 months after receiving a dose of mRNA-1273 (third dose in a Covid19 vaccination schedule).  Maternal exposure before pregnancy was also reported; she received mRNA-1273 approximately 1 and a half months prior to date of last menstrual period.  She took an unspecified drug for Covid19 treatment, after which she became sick again with symptoms of runny nose, tiredness, low fever, cough, and headache.  Additionally, she previously received 2 doses of a different Covid19 vaccine Pfizer (interchange of vaccine products/revaccination with different Covid19 vaccine).  The ongoing Covid19 pandemic could be a contributory factor.  The benefit risk relationship of mRNA-1273 is not affected by this report.